HomeComparePRBCF vs MRK

PRBCF vs MRK: Dividend Comparison 2026

PRBCF yields 1052.63% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRBCF wins by $29512389.22M in total portfolio value
10 years
PRBCF
PRBCF
● Live price
1052.63%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29512389.28M
Annual income
$24,865,533,772,207.38
Full PRBCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — PRBCF vs MRK

📍 PRBCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRBCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRBCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRBCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRBCF
Annual income on $10K today (after 15% tax)
$89,473.68/yr
After 10yr DRIP, annual income (after tax)
$21,135,703,706,376.27/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, PRBCF beats the other by $21,135,703,697,779.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRBCF + MRK for your $10,000?

PRBCF: 50%MRK: 50%
100% MRK50/50100% PRBCF
Portfolio after 10yr
$14756194.67M
Annual income
$12,432,766,891,160.58/yr
Blended yield
84.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PRBCF
No analyst data
Altman Z
2.1
Piotroski
3/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRBCF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRBCFMRK
Forward yield1052.63%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$29512389.28M$57.7K
Annual income after 10y$24,865,533,772,207.38$10,113.78
Total dividends collected$29159831.22M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PRBCF vs MRK ($10,000, DRIP)

YearPRBCF PortfolioPRBCF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$115,963$105,263.16$11,213$373.04+$104.8KPRBCF
2$1,264,889$1,140,808.24$12,667$512.06+$1.25MPRBCF
3$12,982,935$11,629,504.04$14,439$708.14+$12.97MPRBCF
4$125,449,028$111,557,287.82$16,640$988.16+$125.43MPRBCF
5$1,141,645,861$1,007,415,400.94$19,432$1,394.07+$1141.63MPRBCF
6$9,789,747,608$8,568,186,536.38$23,057$1,992.90+$9789.72MPRBCF
7$79,141,579,327$68,666,549,386.16$27,889$2,894.79+$79141.55MPRBCF
8$603,475,154,069$518,793,664,189.69$34,518$4,286.29+$603475.12MPRBCF
9$4,342,855,615,350$3,697,137,200,495.55$43,912$6,494.35+$4342855.57MPRBCF
10$29,512,389,280,631$24,865,533,772,207.38$57,714$10,113.78+$29512389.22MPRBCF

PRBCF vs MRK: Complete Analysis 2026

PRBCFStock

Precise Biometrics AB (publ) offers identification software for the secure authentication of people's identity in Europe, Asia, and the United States. It provides Precise YOUNiQ that verifies digital identity; Precise BioMatch Card, a fingerprint algorithm solution for identity authentication in smart cards; Precise BioMatch Mobile, a fingerprint algorithm solution for identity authentication in smartphones and tablets; and Precise BioLive, a fingerprint software that identifies a fake fingerprint. The company offers its products to sensor manufacturers, security companies, and system integrators, as well as finance, betting, healthcare, and transport sectors. Precise Biometrics AB (publ) was incorporated in 1997 and is headquartered in Lund, Sweden.

Full PRBCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PRBCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRBCF vs SCHDPRBCF vs JEPIPRBCF vs OPRBCF vs KOPRBCF vs MAINPRBCF vs JNJPRBCF vs ABBVPRBCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.